Online inquiry

IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15352MR)

This product GTTS-WQ15352MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ENG gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000118.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2022
UniProt ID P17813
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15352MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6037MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ15282MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ8312MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ6660MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ10925MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ8848MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ11324MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ8572MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW